As health systems continue to focus on reducing the impact of healthcare-associated infections (HAIs) on patients and providers, the Johnson & Johnson Medical Devices Companies (JJMDC) can support health systems’ efforts by bringing expertise from across the broad JJMDC portfolio.

Target Infection. Focus on Prevention.

JJMDC offers tailored approaches to help implement evidence-based practices aimed at addressing risk factors for bloodstream infections (BSIs) and surgical site infections (SSIs), including patient resources to facilitate optimal wound healing post-surgery.

With a unique combination of clinical knowledge, supply chain expertise, and financial acumen, JJMDC can help get you to where you want to be tomorrow.

50%

SSIs and BSIs account for more than half of the total annual costs associated with the most common HAIs13*

6%

Due to pay-for-performance programs under the ACA, infections put over 6% of a facility’s inpatient Medicare reimbursement at risk14,15

*HAIs = Healthcare-associated infections
ACA = Affordable Care Act